SCHEMBL2822792

SCHEMBL2822792

COC(=O)C1CC(N(Cc2ccccc2)C(=O)OC(C)(C)C)CN1Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.50
CETP P11597 2/20 0.43
JAK2 O60674 1/20 0.42
JAK1 P23458 1/20 0.42
KMT2A Q03164 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
NCOR2 Q9Y618 1/20 0.39
OPRM1 P35372 1/20 0.39
NR1H4 Q96RI1 1/20 0.39
CYP3A4 P08684 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
KDM1A O60341 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
AKT1 P31749 2/20 0.38
KLK5 Q9Y337 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13841889 1.00 HSD11B1 (0.50) HSD11B1CETPJAK2JAK1KMT2A
SCHEMBL13841892 0.90 HSD11B1 (0.52) HSD11B1CETPJAK2JAK1KMT2A
SCHEMBL2824379 0.90 HSD11B1 (0.52) HSD11B1CETPJAK2JAK1KMT2A
SCHEMBL2818863 0.86 HTR2A (0.44) HSD11B1CETPOPRM1KDM1AHDAC8
SCHEMBL29930557 0.85 NPFFR1 (0.50) HSD11B1OPRM1NR1H4CYP3A4ALDH1A1
SCHEMBL29930039 0.84 ATM (0.41) HSD11B1CETPNR1H4KDM4EALDH1A1
SCHEMBL30638156 0.80 HSD11B1 (0.46) HSD11B1CETPJAK2JAK1L3MBTL1
SCHEMBL13841900 0.80 HSD11B1 (0.43) HSD11B1CETPJAK2JAK1AKT1
SCHEMBL2817569 0.80 HSD11B1 (0.43) HSD11B1CETPJAK2JAK1AKT1
SCHEMBL26966069 0.80 HSD11B1 (0.52) HSD11B1CETPJAK2JAK1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155672-B1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-10-27 EP disclosed
EP-2155672-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS F. Hoffmann-Roche AG (CH) 2010-02-24 EP disclosed
US-7528136-B2 for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD); 2-{4-[(2S,4S)-1-benzyl-4-(2,4-difluoro-benzylamino)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US disclosed
WO-2008148689-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2008-12-11 WO disclosed
US-20080306086-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306086-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS SLC6A3, OPRL1, OPRK1 HSD11B1 2349/4885CETP 4629/4885JAK2 703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.